Marksans Pharma Dividend 2026 — Rs 0.90 Final Dividend, 0.27% Yield Analysis

Marksans Pharma Limited (NSE: MARKSANS · BSE: 524404 · ISIN: INE750C01026) has declared a final dividend of ₹0.90 per equity share for the financial year 2025-26. Because the face value of the share is only Re 1, the company describes this as a 90% dividend. That headline "90%" is calculated on face value, not on the market price — so it does not mean investors earn 90% on their money. Measured against the current market price of about ₹330, the real dividend yield is only about 0.27%.

The one-line takeaway: This is a small, comfortably affordable dividend from a debt-light, cash-rich generics company. The payout is highly secure, but the income yield is tiny — Marksans is a growth-and-capital-appreciation story, not an income stock. Numbers marked "Not Disclosed by Company" or "NIV" (not independently verified) are flagged as such rather than estimated.

At its board meeting on 26 May 2026, the Board of Directors of Marksans Pharma recommended a final dividend of ₹0.90 per equity share of face value Re 1 (90%) for FY2025-26. The recommendation was made alongside the audited standalone and consolidated results for the quarter and year ended 31 March 2026, on which the statutory auditors (MSKA & Associates LLP) issued an unmodified (clean) opinion.

Context that the wire reports skip: the ₹0.90 dividend is a 12.5% increase over last year's ₹0.80, continuing an unbroken run of rising dividends. But the increase in the rupee amount is far smaller than the growth in the company's cash pile and profits — the payout ratio has stayed pinned at roughly 10%.

The record date is the cut-off used to decide who is eligible to receive the dividend. The ex-date is the first day the share trades without the right to the dividend — under India's T+1 settlement, the ex-date and record date now typically coincide. The ex-date shown here is inferred on that convention and should be confirmed against the official NSE/BSE corporate-action circular. Because the record date has already passed, eligibility for this dividend is now fixed.

The "90%" number is a face-value illusion

Indian companies quote dividends as a percentage of face value. Marksans has a face value of Re 1, so ₹0.90 works out to a "90% dividend." That figure tells you nothing about the return on your investment. The number that matters is the dividend yield, which divides the dividend by the actual share price.

For perspective, the Indian pharmaceuticals sector average dividend yield is around 0.8% (Simply Wall St). At ~0.27%, Marksans yields roughly a third of the sector average — a clear signal that management prioritises reinvestment and acquisitions over cash returns.

Operating leverage: revenue and profit moved together

Revenue, EBITDA and total income all grew at almost exactly the same pace (~12.5–12.8%), and the operating margin held steady near 20%. That is a sign of a stable, well-controlled cost base — there was no margin compression or cost blow-out this year. Net profit grew slightly slower (+9.8%) than EBITDA, mainly because finance costs more than doubled (₹11.7 cr to ₹24.1 cr) as the company drew on working-capital funding, and depreciation rose with its expanding asset base.

Reported profit is an accounting opinion; cash is a fact. A dividend can only be paid out of cash. So the key question is: does the business actually generate the cash it reports as profit? For Marksans in FY26, the answer is a clear yes.

How the dividend is funded

The ₹40.78 cr dividend is funded entirely from current-year earnings and free cash flow. It is not being paid from cash reserves, asset sales or borrowings. Free cash flow of ₹328 cr covers the payout roughly 8 times over. One watch-point: inventory days have crept up to ~278 and the cash-conversion cycle to ~261 days (Screener), typical of a generics exporter building stock for regulated markets — worth monitoring but not a dividend risk today.

Composite verdict: Highly Sustainable

The dividend passes all four tests comfortably. Earnings cover it 10x, operating cash flow 11x, free cash flow 8x, and total cash more than 31x. Earnings are growing, debt is negligible and cash is rising. The only realistic "risk" to this dividend is that management chooses to keep it small on purpose — the constraint is willingness to pay, not ability to pay.

Marksans stands out for its low payout ratio. Established formulation peers such as Ajanta Pharma and JB Chemicals return 35–40% of profits as dividends and yield around 1%. Marksans returns only ~10% and yields a third of the sector average. On returns, however, Marksans holds its own with ROE ~15% and ROCE ~19%. The message: Marksans is choosing growth and cash accumulation over shareholder distributions.

How dividends are taxed in India

Since April 2020, dividends are taxed in the hands of the investor at their applicable income-tax slab rate (the company no longer pays Dividend Distribution Tax). The company deducts TDS of 10% under Section 194 only if the total dividend paid to a resident shareholder by that company exceeds ₹10,000 in a financial year (this threshold was raised from ₹5,000 in the 2025 Budget). If your PAN is not linked, TDS is 20%.

• Income-investor mismatch: at ~0.27% yield (about a third of the pharma sector's ~0.8%), Marksans offers almost no dividend income. Anyone buying for regular cash flow will be disappointed.
• Payout policy is deliberately low: the ~10% payout ratio has not moved in three years despite surging cash. There is no stated dividend policy committing management to raise it, so the dividend may stay token even as profits grow.
• US/regulated-market dependence: most revenue comes from the US, UK/Europe and Australia. USFDA inspections, price erosion in US generics, and product recalls can hit profits — and therefore the pool from which dividends are paid.
• Currency exposure: a meaningful slice of "other income" is foreign-exchange gains (~₹50 cr in FY26). A reversal of the rupee's movement could reduce reported profit even if the underlying business is unchanged.
• Working-capital build-up: inventory days (~278) and the cash-conversion cycle (~261 days) have risen. If cash gets increasingly tied up in stock and receivables, free cash flow — and dividend headroom — could tighten in future years.
• Acquisition-led strategy: management is actively acquiring companies (ABCnow GmbH, QliniQ B.V., new Ireland/Canada subsidiaries). Capital directed to M&A is capital not returned as dividends, and integration carries execution risk.

• Payout ratio trend: watch whether management lifts the payout above ~10% or announces a formal dividend/capital-return policy. That would be the single biggest signal for income-focused investors.
• Free cash flow direction: FY26 FCF jumped to ₹328 cr. Track whether this holds as capex and acquisitions scale up — sustained FCF is what underwrites future dividend growth.
• Working-capital cycle: monitor inventory and debtor days each quarter; a further rise would signal cash being trapped in the balance sheet.
• USFDA / regulatory status: follow inspection outcomes (EIR, VAI, warning letters) at Marksans and its subsidiaries' facilities, as these directly affect the US business.
• Acquisition returns: assess whether recent buys (ABCnow, QliniQ) and new geographies add to profit and cash, or dilute returns.
• Margin trajectory: the ~20% operating margin is the anchor of profitability — watch for raw-material, freight or employee-cost pressure that could compress it.

Marksans Pharma's FY26 dividend is best understood as a small, symbolic, and extremely safe distribution from a fast-growing, cash-rich generics company. The dividend's safety is not in question — but its size is deliberately modest, and the yield is negligible. This is a business geared toward capital appreciation and reinvestment, not dividend income. Whether that suits you depends entirely on your own goals; the facts, positives, negatives and risks are laid out above for you to decide.

This article is for informational and educational purposes only and does not constitute investment, financial, legal or tax advice, nor a recommendation to buy, sell or hold any security. ShareBazaar Online is not a SEBI-registered investment adviser or research analyst. Dividend amounts, dates and financial figures are based on the company's stock-exchange filings and third-party data sources believed to be reliable as of publication; figures may be revised, and all price-dependent numbers (such as dividend yield) change with the market price. Investors must independently verify all figures, including the live market price, record date and ex-date, against official NSE/BSE circulars and the company's filings before making any decision. Investments in securities are subject to market risks; past performance and past dividends are not indicative of future results. Please consult a SEBI-registered adviser and a qualified tax professional for guidance specific to your situation.